Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

122.23B

Market cap122.23B

Price-Earnings ratio

13.06

Price-Earnings ratio13.06

Dividend yield

4.23%

Dividend yield4.23%

Average volume

14.36M

Average volume14.36M

High today

$61.48

High today$61.48

Low today

$59.54

Low today$59.54

Open price

$61.10

Open price$61.10

Volume

13.77M

Volume13.77M

52 Week high

$68.64

52 Week high$68.64

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

With a market cap of 122.23B, Bristol-Myers Squibb(BMY) trades at $60.19. The stock has a price-to-earnings ratio of 13.06 and currently yields dividends of 4.23%.

On 2026-10-17, Bristol-Myers Squibb(BMY) stock traded between a low of $59.54 and a high of $61.48. Shares are currently priced at $60.19, which is +1.1% above the low and -2.1% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 13.77M, against a daily average of 14.36M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

BMY News

The Motley Fool 14h

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Mye...

Simply Wall St 3d

Why Bristol-Myers Squibb Is Back In The Spotlight

Bristol-Myers Squibb (BMY) is back in focus after reporting positive Phase 3 data for two late stage drugs: RYZ101 in gastroenteropancreatic neuroendocrine tumo...

TipRanks 5d

Risk-Reward Unfavorable for Bristol-Myers Squibb: Sell Rating Reiterated with Unchanged $41 Price Target

Morgan Stanley analyst Terence Flynn maintained a Sell rating on Bristol-Myers Squibb today and set a price target of $41.00. Terence Flynn has given his Sell...

Analyst ratings

58%

of 31 ratings

Buy

35.5%

Hold

58.1%

Sell

6.5%

More BMY News

TipRanks 5d

Bristol-Myers Squibb: Zenbexus Phase III Validates Benefit but Competitive Pressures Keep Risk/Reward Balanced at Hold

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on October 9. Matt Phipps has given his Hold rating du...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.